EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BB Biotech AG's enterprise value is €2,451.94 Mil.
BB Biotech AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil. Therefore, BB Biotech AG's EV-to-EBITDA for today is .
The historical rank and industry rank for BB Biotech AG's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of BB Biotech AG was 41.50. The lowest was 0.00. And the median was 27.90.
LSE:0JYO's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 10.52 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
BB Biotech AG EV-to-EBITDA Historical Data
The historical data trend for BB Biotech AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BB Biotech AG's EV-to-EBITDA
For the Biotechnology subindustry, BB Biotech AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's EV-to-EBITDA falls into.
BB Biotech AG EV-to-EBITDA Calculation
BB Biotech AG's EV-to-EBITDA for today is calculated as:
BB Biotech AG's current Enterprise Value is €2,451.94 Mil.
BB Biotech AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BB Biotech AG (LSE:0JYO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
BB Biotech AG's PE Ratio for today is calculated as:
BB Biotech AG's share price for today is €189.39.
BB Biotech AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of BB Biotech AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:0JYO has been successfully added to your 